Science Explorer Back to mapMap

Most cited papers from Frontier Agriculture (United Kingdom)

What are the most cited papers from Frontier Agriculture (United Kingdom)?

The most cited paper from Frontier Agriculture (United Kingdom) is "2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial" (Ian Smith et al., 2007), with 1,521 citations. Next come "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial" (1,324) and "11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial" (1,052).

Showing 50 of 59 papers. Every paper with more than 40 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Ian Smith et al. · The Lancet 2007 1,521
2 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial José Baselga et al. · The Lancet Open access 16 Jan 2012 1,324
3 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial David Cameron, Martine J Piccart, Richard D. Gelber et al. · The Lancet Open access 16 Feb 2017 1,052
4 Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab Roberto Salgado, Carsten Denkert, Christine E. Campbell et al. · JAMA Oncology Open access 30 Apr 2015 621
5 Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Luca Gianni et al. · The Lancet Oncology 26 Feb 2011 614
6 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch et al. · The Lancet 17 Jul 2013 504
7 Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer et al. · Annals of Oncology Open access609 authors 10 Oct 2022 477
8 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response Evandro de Azambuja et al. · The Lancet Oncology 14 Aug 2014 461
9 Corticosteroids for Bell's palsy (idiopathic facial paralysis) Vishnu B. Madhok, Ildikó Gágyor, Fergus Daly et al. · Cochrane Database of Systematic Reviews Open access 18 Jul 2016 390
10 Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up Martine J Piccart et al. · Journal of Clinical Oncology Open access 4 Feb 2021 374
11 Population-Based Colonoscopy Screening for Colorectal Cancer Michael Bretthauer et al. · JAMA Internal Medicine Open access 23 May 2016 329
12 Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy: a multicentre, observational study Krzysztof Budzyń et al. · ˜The œLancet. Gastroenterology & hepatology 12 Aug 2025 265
13 PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab S. Loibl, Ian J. Majewski, Valentina Guarneri et al. · Annals of Oncology Open access 13 May 2016 236
14 CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) Bernhard C. Pestalozzi, Eileen McCormick Holmes, Evandro de Azambuja et al. · The Lancet Oncology 12 Feb 2013 213
15 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Michael Untch et al. · Annals of Oncology Open access 23 Feb 2008 198
16 Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Philippe Georges Aftimos et al. · Cancer Discovery Open access 28 Jun 2021 187
17 Effectiveness of Acupuncture for Low Back Pain Jing Yuan, Nithima Purepong, Daniel Paul Kerr et al. · Spine 28 Oct 2008 178
18 Antiviral treatment for Bell's palsy (idiopathic facial paralysis) Ildikó Gágyor, Vishnu B. Madhok, Fergus Daly et al. · Cochrane Database of Systematic Reviews Open access 9 Nov 2015 176
19 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO Géraldine Gebhart, Cristina Gámez, Eileen McCormick Holmes et al. · Journal of Nuclear Medicine Open access 3 Oct 2013 162
20 Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Françoise Rothé et al. · Clinical Cancer Research Open access 12 Mar 2019 130
21 Antibodies to TR2 (Herpesvirus Entry Mediator), a New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines Jeremy Harrop, Manjula P Reddy, Kimberly Dede et al. · The Journal of Immunology Open access Aug 1998 127
22 The impact of a bodyweight and physical activity intervention (BeWEL) initiated through a national colorectal cancer screening programme: randomised controlled trial Annie S. Anderson, Angela Mary Craigie, Stephen Caswell et al. · BMJ Open access 7 Mar 2014 119
23 Rationale and design of the European Polyp Surveillance (EPoS) trials Rodrigo Jover et al. · Endoscopy Open access 4 Apr 2016 113
24 Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients Matteo Lambertini et al. · JNCI Journal of the National Cancer Institute Open access 18 Apr 2018 105
25 Online support groups for women with breast cancer Eilís McCaughan, Kader Parahoo, Irene Hueter et al. · Cochrane Database of Systematic Reviews Open access 10 Mar 2017 98
26 Pedometer-driven Walking for Chronic Low Back Pain Suzanne McDonough, Mark A. Tully, Adele Boyd et al. · Clinical Journal of Pain Open access 27 Feb 2013 95
27 Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer Jens Huober et al. · European Journal of Cancer Open access Aug 2019 90
28 A key to the Lichen-Forming, Parasitic, Parasymbiotic and Saprophytic Fungi Occurring on Lichens in the British Isles David L. Hawksworth · The Lichenologist Feb 1983 90
29 Cross-trimester repeated measures testing for Down’s syndrome screening: an assessment Donald S. Wright, Ian Bradbury, Fergal Desmond Malone et al. · Health Technology Assessment Open access Jul 2010 90
30 Valuation framework for large scale electricity storage in a case with wind curtailment Rodica Loisel, Arnaud Mercier, Christoph Gatzen et al. · Energy Policy 22 Aug 2010 88
31 Declining Business Dynamism in the U.S. High-Technology Sector John Haltiwanger, Ian Hathaway, Javier Miranda · SSRN Electronic Journal PreprintOpen access 2014 84
32 Lung Clearance Index is a Repeatable and Sensitive Indicator of Radiological Changes in Bronchiectasis Stephen Rowan, Judy Martina Bradley, Ian Bradbury et al. · American Journal of Respiratory and Critical Care Medicine Mar 2014 76
33 Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01) Hatem A. Azim, Otto Metzger, Evandro de Azambuja et al. · Breast Cancer Research and Treatment 25 Feb 2012 75
34 Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials Matteo Lambertini, Samuel Martel, Christine E. Campbell et al. · Cancer Open access 18 Oct 2018 73
35 Enhancement of artemisinin concentration and yield in response to optimization of nitrogen and potassium supply to Artemisia annua Michael J. Davies, Christopher John Atkinson, Corrinne Burns et al. · Annals of Botany Open access 30 May 2009 71
36 A pooled analysis of the cardiac events in the trastuzumab adjuvant trials Evandro de Azambuja, Noam Falbel Ponde, Marion Jennifer Procter et al. · Breast Cancer Research and Treatment Open access 11 Oct 2019 70
37 Education of healthcare professionals for preventing pressure ulcers Alison P Porter-Armstrong, Zena Moore, Ian Bradbury et al. · Cochrane Database of Systematic Reviews Open access 25 May 2018 69
38 Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study Rina Hui et al. · Clinical Cancer Research Open access 16 Oct 2019 64
39 Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) Noam Falbel Ponde et al. · Breast Cancer Research and Treatment Open access 26 Dec 2017 62
40 Exercise and Auricular Acupuncture for Chronic Low-back Pain Ruth Fiona Hunter, Suzanne McDonough, Ian Bradbury et al. · Clinical Journal of Pain 13 Jul 2011 62
41 A few things transport regulators should know about risk and the cost of capital Ian Alexander, Antonio Estache, Adele Oliveri · Utilities Policy Mar 2000 61
42 Tech Starts: High-Technology Business Formation and Job Creation in the United States Ian Hathaway · SSRN Electronic Journal PreprintOpen access 2013 60
43 Ex post appraisal: What lessons can be learnt from EU cohesion funded transport projects? Charlotte M Kelly, James J. Laird, Stefano Costantini et al. · Transport Policy 14 Nov 2014 57
44 Development of an X-ray computed tomography (CT) system with sparse sources: application to three-phase pipe flow visualization Bin Hu, Colin J. Stewart, Colin P. Hale et al. · Experiments in Fluids 24 Jun 2005 54
45 The gut metabolite indole-3-propionic acid activates ERK1 to restore social function and hippocampal inhibitory synaptic transmission in a 16p11.2 microdeletion mouse model Jian Wei Jiang, Dilong Wang, Youheng Jiang et al. · Microbiome Open access 28 Mar 2024 52
46 VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Annals of Oncology Open access 15 Jul 2022 52
47 Mobile Termination: What is the “Right” Charge?* Tommaso Valletti, George Houpis · Journal of Regulatory Economics 4 Oct 2005 51
48 RaVÆn: unsupervised change detection of extreme events using ML on-board satellites Vít Růžička, Anna Vaughan, Daniele De Martini et al. · Scientific Reports Open access 8 Oct 2022 50
49 Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial Carmen Criscitiello, Hatem A. Azim, Dominique Agbor‐Tarh et al. · Annals of Oncology Open access 9 Apr 2013 50
50 Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer Michail Ignatiadis et al. · JAMA Open access 30 Jan 2025 49

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.